Actualités et Activités de NextCure

NextCure est une société cotée sous le symbole boursier NXTC (US).

Voir l'organigramme avec ses 25 principaux dirigeants

Biographies les plus recherchées chez NextCure

• Michael Richman, Director, President and Chief Executive Officer
• Elaine Jones, Director
• David Kabakoff, Chairman of the Board

Créer une alerte
pour suivre les mouvements de dirigeants chez NextCure.

NextCure a 2 428 concurrents dont Lonza (Suisse), Vertex Pharmaceuticals (Etats—Unis) et Eurofins (Luxembourg).

Actualités en fusion/acquisition en Biotechnologie.

• Eli Lilly has announced the acquisition of AtaiBeckley  (publié le 17 juillet 2026).
• GSK a acquis Nuvalent (publié le 17 juillet 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publié le 15 juillet 2026).

Contacts en Biotechnologie

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer chez Inceptive
• Jan Van de Winkel - President and Chief Executive Officer chez Genmab
• Robert Gould - Board Member chez Fulcrum Therapeutics

En savoir plus sur le secteur Biotechnologie

Derniers communiqués de presse par NextCure

• NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers - NextCure, Inc.
• NextCure Announces Acceptance of IND Application for LNCB74 - NextCure, Inc.
• Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta - NextCure, Inc.
• NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results - NextCure, Inc.
• NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting - NextCure, Inc.
• NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - NextCure, Inc.
• NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024 - NextCure, Inc.
• NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results - NextCure, Inc.
• NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - NextCure, Inc.
• NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 - NextCure, Inc.
• Voir plus de communiqués de presse Close

Réseaux sociaux à propos de NextCure

• NextCure sur Wikipédia, Google News & Yahoo Finance en 1-click
• NextCure sur LinkedIn, X (Twitter) & YouTube en 1-click